ClinicalTrials.gg
RecruitingNCT04679740Updated Nov 21, 2025

Resorbable Magnesium Scaffolds Registry

An observational study in Coronary Artery Disease, sponsored by Biotronik AG. Recruiting at 13 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,106
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG — 1 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Biotronik SE & Co. KG.

Planned enrollment
5th of 20
1,106 · median 528
Started
2020
with 4 others
Observational
20 of 37
1 open now
Registered
36th of 37
by date

Among the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2020, is one of 20 observational ones, and was the 36th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG is open now, in 7 countries.

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Registry
  • Magmaris
  • Coronary Artery Disease
  • PCI
  • Resorbable Magnesium Scaffolds
  • Freesolve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic coronary artery disease needing the treatment of de novo native coronary artery lesions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • According to the IFU

Exclusion criteria

Exclusion Criteria:

  • According to the IFU
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,106 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • DeviceMagmaris

    MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.

    Also known as: Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold

  • DeviceFreesolve

    Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.

    Also known as: Freesolve Sirolimus-Eluting Coronary Resorbable Magnesium Scaffold (RMS) System

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF)

    The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).

    Time frame: 12 months

07

Study locations

6 of 13 sites recruiting
  • Cairns Hospital
    Cairns, 4870, Australia
    Completed

    Not enrolling at this site.

  • Heart Center Segeberger Kliniken
    Bad Segeberg, 23795, Germany
    Recruiting
    • Holger Nef, MD · Contact
    • Ralph Toelg, MD · Contact
  • Krankenhaus Buchholz
    Buchholz, 21244, Germany
    Completed

    Not enrolling at this site.

  • Klinikum Westfalen, Knappschaft KH
    Dortmund, 44309, Germany
    Completed

    Not enrolling at this site.

  • Klinikum Herford
    Herford, 32049, Germany
    Completed

    Not enrolling at this site.

  • Herz-und Gefäßzentrum Oberallgäu-Kempten
    Kempten, Germany
    Completed

    Not enrolling at this site.

  • Centro Cardiologico Monzino
    Milan, Lombardy 20138, Italy
    Recruiting
    • Stefano Galli, MD · Contact
  • Daugavpils Regional Hospital
    Daugavpils, LV-5417, Latvia
    Completed

    Not enrolling at this site.

  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ w Lublinie
    Lublin, Poland
    Recruiting
    • Grzegorz Sobieszek, MD · Contact
  • SUSCCH Banska Bystrica
    Banská Bystrica, 974 01, Slovakia
    Completed

    Not enrolling at this site.

  • Lindenhofspital
    Bern, 3001, Switzerland
    Recruiting
    • Samera Shakir, MD · Contact
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, 1005, Switzerland
    Recruiting
    • Stephane Fournier, MD · Contact
  • Solothurner Spitäler AG
    Olten, 4600, Switzerland
    Recruiting
    • Yves Laurent Bayard, MD · Contact
08

References and documents

Publications

  • Wolbert S, Schmidt T, Wittek F, Mayer B, Raake P, Bongiovanni D, Torzewski J. One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions. Front Cardiovasc Med. 2026 Jun 12;13:1854686. doi: 10.3389/fcvm.2026.1854686. eCollection 2026. PubMed 42368841 ↗

Individual participant data

Plan to share: No — The primary outcome data will be shared after the publication of it.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for May 2030, 114 months after the start.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 114 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 22, 2020
StartActual
Nov 18, 2020
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04679740
Lead sponsor
Biotronik AG
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Nov 18, 2020
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 21, 2025

Study contacts

Marina Gattiglio, Dr.
Contact
marina.gattiglio@teleflex.com
+41754295843
Stefano Galli, MD
principal investigator · Centro Cardiologico Monzino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion